Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03122496 · ClinicalTrials.gov registry record · Phase 1
Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT03122496: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03122496 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03122496, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of durvalumab (MEDI4736) and tremelimumab in combination with radiation therapy and find out what effects, if any, this combination has on people, and whether it improves overall survival.
Interventions
- DRUG durvalumab
- RADIATION Stereotactic Body Radiotherapy (SBRT)
- DRUG tremelimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2017-04-25 |
| Est. Completion | 2022-06-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03122496
The ClinicalTrials.gov registry entry for NCT03122496 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which durvalumab is the first listed.
NCT03122496 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03122496 about?
NCT03122496 is a clinical study titled "Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer". The purpose of this study is to test the safety of durvalumab (MEDI4736) and tremelimumab in combination with radiation therapy and find out what effects, if any, this combination has on people, and whether it improves overall survival.
What is the current status of trial NCT03122496?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2017-04-25. Estimated completion is 2022-06-03.
What interventions are being tested in trial NCT03122496?
The interventions under investigation include: durvalumab (DRUG), Stereotactic Body Radiotherapy (SBRT) (RADIATION), tremelimumab (DRUG).
Who is sponsoring clinical trial NCT03122496?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.